Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricleHeart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administrati ...

The latest trading session saw Medtronic (MDT) ending at $83.75, denoting a +0.46% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 1.67%. Meanwhile, the Dow experienced a rise of 1.07%, and the technology-dominated Nasdaq saw an increase of 2.5%.Prior to today's trading, shares of the medical device company had lost 5.89% over the past month. This has was narrower than the Medical sector's loss of 9.34% and the S&P 500's loss of 6.57% in that time.The investment community ...

FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac functionSymposium will also feature pr ...

Hi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend investing since about 2009.Since July 2018, I have ran Kody's Dividends. This is a blog that is documenting my journey towards financial independence using dividend growth investing as the means to transform the dream of financial independence into a reality. It's also th ...

Medtronic TodayMDTMedtronic$82.80 +1.00 (+1.22%) 52-Week Range$75.96▼$96.25Dividend Yield3.38%P/E Ratio25.17Price Target$96.14Add to WatchlistInvestors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to identify companies with strong fundamentals, defensive strategies, and dependable shareholder returns. Medtronic plc NYSE: MDT, a leading global healthcare technology company, stands out as a compelling option. It offers a ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It’s good to keep a cool head amidst market volatility. While the first reaction may be to hit the sell button, those with a long-term horizon may want to pu ...

Latest approval expands Medtronic CGM portfolio in the U.S.GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection™ technology with both the Guardian™ ...

文章核心观点 - 美敦力公司因产品Evolut经导管主动脉瓣置换（TAVR）系统的利好消息，股价在交易周开始时上涨近3%，跑赢标普500指数 [1] 分组1：股价表现 - 美敦力股票在交易周开始时受投资者推动，股价上涨近3%，涨幅轻松超过标普500指数当日0.6%的涨幅 [1] 分组2：产品试验情况 - 周日美敦力公布其Evolut TAVR系统低风险临床试验的五年数据，该系统用于治疗主动脉瓣狭窄，试验将其与外科主动脉瓣置换（SAVR）进行对比，参与者均患有严重的主动脉瓣狭窄 [2] - TAVR在全因死亡率或致残性中风方面与SAVR相当，且使用美敦力设备的患者在五年内表现出更优的瓣膜性能 [2][3] 分组3：产品前景 - 美敦力结构心脏部门首席医疗官称Evolut在五年时显示出与手术相当的持久临床效果，且有降低心血管死亡率的趋势 [3] - 每年约有30万例严重主动脉瓣狭窄被诊断出来，美敦力的消息增强了Evolut的应用前景 [3]

文章核心观点 公司公布2024年全年财务业绩并提供第四季度业务更新，聚焦BACKBEAT全球关键研究和Virtue SAB项目推进，同时与泰尔茂的合作谈判进入调解程序 [1][2] 公司业务进展 - 持续推进BACKBEAT全球关键研究的站点激活和患者招募，评估AVIM疗法在高血压起搏器患者中的疗效和安全性 [5] - 向FDA提交Virtue ISR - US关键研究的修订设计，预计2025年下半年启动，待FDA在二季度批准修订的研究设备豁免申请 [5] - 与泰尔茂进入调解程序，目标在2025年二季度结束谈判 [5] - 任命三位经验丰富的独立董事增强董事会实力 [5] - 任命Mark Pomeranz为介入治疗执行副总裁兼总经理，加强高级领导团队 [5] 公司产品信息 - AVIM疗法与标准双腔起搏器兼容，可显著持久降低血压，BACKBEAT全球关键研究将进一步评估其安全性和有效性 [8] - Virtue SAB是用于治疗特定动脉疾病的药物/设备组合产品，在SABRE研究中显示出积极的三年临床数据，并获得FDA突破性设备指定 [9][11] 公司财务状况 - 截至2024年12月31日，现金及现金等价物和有价证券总计6680万美元 [10] - 2024年现金流入包括约1500万美元的普通股销售净现金收益和约1500万美元的信贷额度初始提款 [10] - 2024年经营活动和固定资产购置净现金使用量为5080万美元，高于2023年的4620万美元，主要因研发现金流出增加 [10] - 2024年营收为260万美元，低于2023年的280万美元，主要因与泰尔茂合作协议下的合作伙伴收入确认减少 [10] - 2024年研发费用为4280万美元，高于2023年的3380万美元，主要因BACKBEAT全球关键研究的额外成本 [10] - 2024年销售、一般和行政费用为2390万美元，高于2023年的2030万美元，主要因基于股票的薪酬费用增加 [10] - 2024年净亏损为6100万美元，即每股亏损1.66美元，高于2023年的4910万美元和每股亏损1.48美元 [10] 公司资产负债表 - 2024年总资产为7617.3万美元，低于2023年的9521.2万美元 [15] - 2024年总负债为4321.5万美元，高于2023年的2716.9万美元 [15] - 2024年股东权益为3295.8万美元，低于2023年的6804.3万美元 [15] 公司运营和综合亏损表 - 2024年总营收为263.8万美元，低于2023年的276万美元 [16][17] - 2024年总费用为6693.9万美元，高于2023年的5426.6万美元 [17] - 2024年净亏损为6102.4万美元，高于2023年的4912万美元 [17] - 2024年综合亏损为6096.2万美元，高于2023年的4912.2万美元 [17]

文章核心观点 - 公司认为美敦力是值得投资的医疗保健股，因其连续47年提高股息、行业领先地位、业务重组初见成效，有望带来长期可靠收入和资本收益 [2][4][9] 分组1：投资理念 - 优秀的股息股应数十年持续提高股息，公司偏好购买陷入困境但股息率高的股票 [3] 分组2：美敦力股息情况 - 美敦力连续47年每年提高股息，在医疗保健行业中排名第三，近3.1%的股息收益率接近公司历史收益率范围的高端 [4] 分组3：美敦力行业地位 - 美敦力是医疗设备巨头，在心脏护理、神经科学、外科手术和糖尿病管理领域处于领先地位，能进行前沿研究并整合行业 [6] 分组4：美敦力业务问题与解决 - 美敦力因收购导致业务臃肿、难以管理，公司正在进行业务重组、出售非核心资产和提高效率，已初见成效 [8] 分组5：美敦力业务成果 - 2025财年第三季度，美敦力有机销售额增长4.1%，调整后收益增长6.9% [9] 分组6：美敦力股价情况 - 自2022年末以来，美敦力股价下跌约三分之一，长期股息增长型公司股价通常随股息上涨，预计美敦力股价将恢复长期上涨趋势 [11] 分组7：投资美敦力的预期 - 投资美敦力有望获得长期股息和资本收益，建议在其仍不受华尔街青睐时买入 [12]